ArticleDEN open2027
Patients With Pancreatitis-Related Gene Variants Showed Higher Incidence of Hyperpancreatic Enzymemia After Endoscopic Retrograde Cholangiopancreatography.
Article in DEN open, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis (PEP) is the most severe adverse event associated with ERCP. Although numerous studies have identified risk factors for PEP, the role of genetic background in its development remains unexplored. The present study investigated the association between pancreatitis-related gene variants (PRG-variants) and PEP. Methods: This prospective, single-center study included 94 patients with naïve papilla who underwent ERCP between October 2021 and August 2023. Targeted sequencing was performed to analyze variants in four PRGs: Results: PRG-variants, regardless of their pathogenicity, were identified in 16 (17%) patients. Among all cases, PEP occurred in four (4%) patients, and PEH occurred in 27 (29%) patients. The incidence of PEP did not differ significantly with and without PRG-variants ( Conclusions: The present pilot study suggests that patients with PRG-variants, regardless of their pathogenicity, demonstrated a significantly higher incidence of PEH but not PEP. PEH may reflect pancreatic parenchyma injury and may progress to PEP when additional factors are present. Thus, PRG-variants may contribute to biochemical pancreatic injury after ERCP. Further large-scale studies and comprehensive genomic profiling of patients with PEH/PEP are warranted. Trial Registration: The central ethics committee approved the study protocol (M21-0066).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.